Unknown

Dataset Information

0

Pre-symptomatic Caspase-1 inhibitor delays cognitive decline in a mouse model of Alzheimer disease and aging.


ABSTRACT: Early therapeutic interventions are essential to prevent Alzheimer Disease (AD). The association of several inflammation-related genetic markers with AD and the early activation of pro-inflammatory pathways in AD suggest inflammation as a plausible therapeutic target. Inflammatory Caspase-1 has a significant impact on AD-like pathophysiology and Caspase-1 inhibitor, VX-765, reverses cognitive deficits in AD mouse models. Here, a one-month pre-symptomatic treatment of Swedish/Indiana mutant amyloid precursor protein (APPSw/Ind) J20 and wild-type mice with VX-765 delays both APPSw/Ind- and age-induced episodic and spatial memory deficits. VX-765 delays inflammation without considerably affecting soluble and aggregated amyloid beta peptide (Aβ) levels. Episodic memory scores correlate negatively with microglial activation. These results suggest that Caspase-1-mediated inflammation occurs early in the disease and raise hope that VX-765, a previously Food and Drug Administration-approved drug for human CNS clinical trials, may be a useful drug to prevent the onset of cognitive deficits and brain inflammation in AD.

SUBMITTER: Flores J 

PROVIDER: S-EPMC7486940 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC5718953 | biostudies-literature
| S-EPMC6218962 | biostudies-literature
| S-EPMC5770778 | biostudies-literature
2009-01-25 | E-GEOD-9990 | biostudies-arrayexpress
| S-EPMC4439182 | biostudies-literature
| S-EPMC3328757 | biostudies-literature
2014-09-23 | E-GEOD-61326 | biostudies-arrayexpress
| S-EPMC4581900 | biostudies-literature
| S-EPMC6372563 | biostudies-literature
| S-EPMC5496516 | biostudies-literature